BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer mortality. MicroRNAs (miRNAs), small noncoding RNAs, regulate the expression of genes that play roles in human cancer via posttranscriptional inhibition. METHODS: To identify the potential miRNA biomarkers in NSCLC, we downloaded the miRNA expression profile (ID: GSE29248) of NSCLC from the Gene Expression Omnibus (GEO) database and analyzed the differentially expressed miRNAs in NSCLC tissue compared with normal control tissue. Then the targets of these differentially expressed miRNAs were screened and used in network construction and functional enrichment analysis. RESULTS: We identified a total of 17 miRNAs that showed a significantly differential expression in NSCLC tissue. We found that miR-34b and miR-520h might play important roles in the regulation of NSCLC, miR-22 might be a novel biomarker as an oncogene, and miR-448 might promote, while miR-654-3p prevents, NSCLC progression. CONCLUSIONS: Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.BAC
BACKGROUND:Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer mortality. MicroRNAs (miRNAs), small noncoding RNAs, regulate the expression of genes that play roles in humancancer via posttranscriptional inhibition. METHODS: To identify the potential miRNA biomarkers in NSCLC, we downloaded the miRNA expression profile (ID: GSE29248) of NSCLC from the Gene Expression Omnibus (GEO) database and analyzed the differentially expressed miRNAs in NSCLC tissue compared with normal control tissue. Then the targets of these differentially expressed miRNAs were screened and used in network construction and functional enrichment analysis. RESULTS: We identified a total of 17 miRNAs that showed a significantly differential expression in NSCLC tissue. We found that miR-34b and miR-520h might play important roles in the regulation of NSCLC, miR-22 might be a novel biomarker as an oncogene, and miR-448 might promote, while miR-654-3p prevents, NSCLC progression. CONCLUSIONS: Our study may provide the groundwork for further clinical molecular target therapy experiments in NSCLC.BAC
Authors: Anastasia S Nikitina; Elena I Sharova; Svetlana A Danilenko; Tatiana B Butusova; Alexandr O Vasiliev; Alexandr V Govorov; Elena A Prilepskaya; Dmitry Y Pushkar; Elena S Kostryukova Journal: Oncotarget Date: 2017-05-16
Authors: Guilherme Rabinowits; Michaela Bowden; Ludmila M Flores; Sigitas Verselis; Victoria Vergara; Vickie Y Jo; Nicole Chau; Jochen Lorch; Peter S Hammerman; Tom Thomas; Laura A Goguen; Donald Annino; Jonathan D Schoenfeld; Danielle N Margalit; Roy B Tishler; Robert I Haddad Journal: Front Oncol Date: 2017-08-29 Impact factor: 6.244